Metabolism is the sum of chemical reactions which break complex organic molecules down to obtain energy. Complex modifications in glucose and lipid metabolism can cause metabolic diseases such as diabetes mellitus (DM). DM as a global epidemic disorder is responsible for 4 million deaths annually ([@B1], [@B2]). Two types of DM are type1 (T1DM) and type2 (T2DM) ([@B3], [@B4]). Both DM types have a broad range of conventional treatments, which have serious cons points along with their pros points ([@B5]). More recently, by successful development in the therapeutic application of stem cells, the use of stem cells to improve diabetic patientswas remarkable as a novel alternative method ([@B6]). Indeed, stem cell therapy can improve diabetes treatment through differentiation of stem cells into insulin- producing cells, regeneration of pancreas, amending of insulin resistance, and modulation of immune system ([@B7], [@B8]). Due to extensive metabolic rewiring of stem cells during differentiation, reprogramming, and proliferation processes, evaluation of stem cell metabolism via metabolomics approaches have a significant role in controlling stem cell fates ([@B9], [@B10]). On the other hand, metabolomics can distinguish different stem cell types based on their molecular and metabolite biomarkers ([@B11]). Additionally, metabolomics is a potent tool to analyze the complex pathways of disease progression over time, and also it can assay the effects of various treatments ([@B12], [@B13]). Accordingly, the aim of this article was to introduce metabolomics application in cell therapy and regenerative medicine.

Diabetes as a metabolic disorder
================================

Metabolic disorders occur in specific genetic and chemical conditions in which normal cell metabolism is impaired. According to international diabetes federation report, over 425 million people were affected by DM as an example of metabolic disorders around the world ([@B14]). DM diagnosis can be confirmed by hyperglycemia (fasting hypergly-cemia with blood sugar higher than 130 mg/dl and postprandial hyperglycemia with blood sugar higher than 180 mg/dl) resulted from deficiencies in secretion and action of insulin ([@B15]). Involved pathogenic processes in DM are including autoimmune destruction of the pancreatic β-cells followed by insulin deficiency (type 1) and islet cell dysfunction along with insulin resistance (type 2) ([@B13], [@B16]). Some of the long term DM complications including nephropathy leading to renal failure, reduced visual acuity in retinopathy, and peripheral neuropathy with a risk of foot ulcer, introduce it as a global health care burden ([@B16]-[@B18]). Hereupon, treatment of DM is crucial to decrease its later complication risks.

Treatment and management of diabetes
====================================

In order to manage and control DM, a combination therapy including drugs and lifestyle modification is required. With this in view, American Diabetes Association (ADA) and the European Association of Diabetes (EASD) recommended lifestyle modification as the first step of DM management. A suitable diet, regular physical activity and the ideal amount of sleep time are important factors in development of healthier lifestyle. Although a healthy lifestyle is preferable, following a special lifestyle is exhausting for a long time ([@B19], [@B20]). On the other hand, some pharmacological interventions ([Table 1](#T1){ref-type="table"}) are required along with a change in lifestyle.

Despite the different types of pharmacological treatments, and application of some alternative methods such as hydrotherapy, acupuncture, and dietary supplements, definitive treatments for DM has not been announced yet. In recent years, cell-based therapies as hopeful approaches to the treatment of chronic disorders such as DM have been progressed from bench-to-bedside ([@B31]-[@B36]).

###### 

Advantages and disadvantages of diabetes medicines

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Class of Medications**        **Example**                                  **Advantages**                                                                          **Disadvantages**                                                          **Mechanism of action**                                                                                                                                                **References**
  ------------------------------- -------------------------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  **Biguanidas**                  Metformin\                                   Reducing hepatic glucose, fasting glycemia,\                                            Weight loss\                                                               Reducing hepatic glucose output through inhibition of gluconeogenesis                                                                                                  ([@B19], [@B21]-[@B24])
                                  (Glucophag)                                  Hemoglobin A1C                                                                          Anorexia\                                                                                                                                                                                                                                         
                                                                                                                                                                       Nausea\                                                                                                                                                                                                                                           
                                                                                                                                                                       Abdominal discomfort\                                                                                                                                                                                                                             
                                                                                                                                                                       Diarrhea                                                                                                                                                                                                                                          

  **Sulfonylures**                Glibenclamie (Daonil), Gliclazide (Glizid(   Secreting insulin Decreasing glycemia,\                                                 Weight gain\                                                               Increasing insulin secretion regulated by ATP-sensitive potassium channels                                                                                             ([@B19], [@B22], [@B24], [@B25])
                                                                               Hemoglobin A1C                                                                          Hypoglycemia                                                                                                                                                                                                                                      

  **Thiazolidinediones (TZDs)**   Glitazones, Pioglitazone                     Using glucose by increasing the insulin sensitivity in muscle, fat, and liver tissues   Weight gain\                                                               Increasing insulin sensitivity by binding to peroxisome proliferator-activated receptors, improving blood glucose levels by preserving pancreatic beta-cell function   ([@B19], [@B22], [@B26], [@B27])
                                                                                                                                                                       Fluid retention with peripheral edema, risk for congestive heart failure                                                                                                                                                                          

  **Insulin**                                                                  Decreasing hemogolobin A1C,\                                                            Weight gain\                                                               Reducing glucose concentration by increasing glucose uptake or reducing glucose production                                                                             ([@B22], [@B28]-[@B31])
                                                                               Effects on triacylglycerol and HDL cholesterol levels                                   Hypoglycemia\                                                                                                                                                                                                                                     
                                                                                                                                                                       Interactions with other medications, Cardiovascular disease                                                                                                                                                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell Therapy as an alternative treatment for diabetes
=====================================================

The ultimate goals of the DM treatments are including insulin resistance improvement, insulin independence restoration, and control of glycemia ([@B37]). Nowadays, development in the differentiation potential of human stem cells into insulin-producing cells (IPCs) as well as stem cells potential for pancreas regeneration and insulin resistance modification suggests a substantial alternative approach to achieve DM treatments goals ([@B8], [@B9], [@B38], [@B39]). According to investigations, embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), umbilical cord blood stem cells (UCBs), fetal and adult pancreatic ductal cells, hepatic oval cells, and neural progenitor cells have been introduced as potential sources to generate IPCs ([@B40]). However, despite the benefit of their application there are some limitations including immune rejection, genetic abnormalities, and less potential of differentiated IPCs to produce enough insulin. To modulate and control differentiated IPCs for producing enough and proper amount of insulin, understanding and assay of genes, proteins or signaling molecules, and metabolites which are playing significant role, is required ([@B41], [@B42]).

Application of multi-OMICs approaches in cell therapy
=====================================================

Recognizing stem cells properties such as self-renewal and differentiation at the molecular level is helpful for stem cell therapy. Additionally, the stem cell fate can be controlled by the complicated functional mechanisms of genome, transcriptome, proteome, and metabolome ([@B43]). In this context, OMICs approaches provide a holistic view around the molecular mechanisms of stem cells properties and functional mechanism of their genomic, transcriptomic, proteomic, and metabolomic profile. The processes of cell therapy include chain steps such as cells isolation, culture, and stimulation, which are different based on cells variations. These differences may be related to the complicated genome of donor cells. In other word, analyzing of genes expression related to the particular function of cells could be useful for the examination of cell therapy potency ([@B44]). In this regard, genomics technology can analyze the whole genome and gene expression in cells. Furthermore, studies on total RNAs (transcriptome) which are transcribed from cells genome can be also effective. On the other hand, during cell therapy, stem cells can produce some biomolecules and proteins in extracellular space that can each affect the cell based-treatment outcomes ([@B45]). Proteomics investigations have a pivotal role in evaluating the functional mechanism of proteins products. However, metabolic analyzing of stem cells metabolome (the complete set of small-molecules which resulted from cell metabolism) via metabolomics studies is more effective than proteome, transcriptome and genome analyzing ([@B12], [@B46], [@B47]).

Metabolomics applied to diabetes research
=========================================

![Metabolomics in cell therapy. The level of metabolites can be changed after transplantation. Hence, metabolomics can explain the efficacy of treatment by monitoring the metabolites before and after cell therapy via targeted and non-targeted methods (59).](ijmcm-8-41-g001){#F1}

Metabolomics as a new technology for the detection and measurement of all or a range of metabolites in biological samples can recognize many of the metabolic and molecular pathways (metabolism pathways of fatty acids, amino acids, nucleotides, and etc.) associated with DM and its subsequent complications ([@B12], [@B48]). Indeed, metabolomics can be used to monitor the modification of cells and bio fluids metabolites during the course of the DM in comparison with the normal healthy state ([@B5], [@B49], [@B50]). Additionally, application of metabolomics methods specifically nuclear magnetic resonance (NMR) and mass spectrometry (MS) approaches to better understand the mechanism of DM related molecular pathways is fruitful for conducting preventive strategies ([@B5], [@B13], [@B51], [@B52]). On the other hand, metabolomics can analyze the modification of cellular and bio fluids metabolites in patients before and after application of different therapies e.g. cell therapy ([Fig. 1](#F1){ref-type="fig"}) to realize the efficacy of the selected treatment ([@B53]-[@B55]).

Conclusion and future perspectives
==================================

Advances in metabolomics approaches have been invaluable for discovering particular disease biomarkers, and to evaluate the mechanisms of action of various novel treatments (i.e. cell-based therapy) as well as understanding the pathogenesis mechanism of diseases (such as diabetes) through targeted or non- targeted methods to improve diagnosis, prediction, and prognosis ([@B56]-[@B59]). Notable strides in the collection of data and appropriate search of databases for data analyzing have leaded to the rapid development of metabolomics by establishing impressive protocols for sample collection, and data extraction methods along with providing the possibility of computer modeling for disease (metabolomics in systems biology) ([@B60]). With the development and progress of metabolomics methods, designing personalized medicines (prescription of particular treatments for each person) in accordance with specific genomic and metabolic profile of each person can be also progressed ([@B61]-[@B66]). For instance, personalized medicine can be beneficial to manage cases of diabetes with specific strategies that will not be necessarily effective for all patients with same weight, height, and glucose levels. Additionally, it seems that personalized medicine can also be beneficial for diabetes prevention. According to the combination of genetic and metabolic effects on outcomes of therapies, the combination of metabolomics with genomics (such as genome- wide association studies (GWAS)- metabolomics strategy) for decoding the functional mechanisms underlying different treatments can be also helpful. This combination may also clarify which genetic disorders are most simply detectable within the metabolomic investigation ([@B67], [@B68]).

The authors would like to thank Maryam Afshari and Zahra Morteza Beigi for their considerable assistance.

Conflict of Interest
====================

There is no conflict of interest.
